Free Trial
→ SpaceX is offering you shares. Don't take them. (From Behind the Markets) (Ad)tc pixel
NYSEAMERICAN:OGEN

Oragenics Q2 2024 Earnings Report

Oragenics logo
$0.59 -0.01 (-1.33%)
As of 04:10 PM Eastern
ProfileEarnings History

Oragenics EPS Results

Actual EPS
-$15.30
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Oragenics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Oragenics Announcement Details

Quarter
Q2 2024
Date
8/9/2024
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Oragenics Earnings Headlines

Oragenics (NYSEAMERICAN:OGEN) Shares Down 1.5% - Should You Sell?
June 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30820038
Oragenics to Present at Sidoti’s Micro-Cap Virtual Investor Conference May 20-21
May 19, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/oragenics-present-sidoti-micro-cap-124500288.html
He Called NVIDIA at $1.10 – Now He Says, “SELL”
The analyst who called NVIDIA at $1.10 now says sell. According to Alexander Green, Chief Investment Strategist at The Oxford Club, AI is doubling in power every 6 months - and the implications for investors are staggering. Green warns that holding the leading AI stocks could be the wrong move as this shift accelerates. With 41 years of market experience, he says a rare window is open right now - but not for long.tc pixel
June 10 at 1:00 AM  |  The Oxford Club (Ad)
Oragenics to Present at Sidoti's Micro-Cap Virtual Investor Conference May 20-21
May 19, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/19/3297513/0/en/oragenics-to-present-at-sidoti-s-micro-cap-virtual-investor-conference-may-20-21.html
ORAGENICS PROVIDES INVESTOR UPDATE
May 18, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/18/3296615/0/en/oragenics-provides-investor-update.html
Oragenics Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation
May 7, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/07/3290005/0/en/oragenics-signs-letter-of-intent-to-license-cardiodialysis-technology-from-sigyn-therapeutics-to-target-tbi-induced-systemic-inflammation.html
See More Oragenics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Oragenics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Oragenics and other key companies, straight to your email.

About Oragenics

Oragenics (NYSEAMERICAN:OGEN) is a clinical-stage biotechnology company focused on the research and development of novel anti-infective therapeutics targeting oral and mucosal diseases. Headquartered in Tampa, Florida, the company leverages proprietary technologies to address unmet needs in dental and oral healthcare, with an emphasis on innovative treatments that can improve patient outcomes and reduce reliance on traditional antibiotics.

The company’s lead product candidate, Oraprev™, is being developed as a pre-procedural rinse designed to reduce oral microbial load prior to dental procedures. In addition to its dental portfolio, Oragenics is advancing Ogi-04™, a therapeutic candidate for the prevention and treatment of oral mucositis, a common and painful side effect of cancer therapy. Oragenics’ research pipeline also includes earlier-stage programs aimed at broad-spectrum anti-infective applications.

Founded in 1996, Oragenics has built a foundation of proprietary peptide and gene-based platforms that support its drug discovery and development efforts. The company operates primarily in the United States but seeks to establish strategic collaborations to extend its reach into additional markets. Oragenics is listed on the New York Stock Exchange under the ticker symbol OGEN.

Oragenics is led by President and Chief Executive Officer Todd Korth, whose leadership and financial expertise have guided the company’s strategic direction and operational execution. The management team combines scientific experience with regulatory and commercial know-how to advance the company’s clinical programs toward potential commercialization.

View Oragenics Profile
Earnings Tools